We are currently completing a Phase 1a/b clinical trial in patients with advanced or metastatic solid tumors, in collaboration with Celgene Corporation. The Phase 1a portion investigated single agent activity with the Phase 1b in combination with nivolumab. Etigilimab is an anti-TIGIT therapeutic candidate designed to activate the immune system through multiple mechanisms and enable anti-tumor activity. TIGIT (T-cell immunoreceptor with Ig and ITIM domains) is an inhibitory receptor that is thought to prevent T-cells from attacking tumor cells, similar to the inhibitory protein PD-1.

Patient resources

Information on OncoMed's anti-TIGIT clinical program is available here: OMP-313M32 ClinicalTrials.gov. This program is part of OncoMed's collaboration with Celgene Corporation.

Public presentations of data from OncoMed's anti-TIGIT program include:

View clinical studies

For Partnering